First Drug Approved for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma.

Abstract

Cemiplimab-rwlc (Libtayo) is the first drug approved to treat metastatic or locally advanced cutaneous squamous cell carcinoma in patients who are not candidates for curative surgery or curative radiation.Immune-mediated adverse effects can be serious and can affect any organ or tissue. Infusion rea